Evotec AG / Key word(s): Miscellaneous
Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
08-March-2018 / 07:42 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec.
Sanofi will licence its infectious disease research and early-stage development portfolio and transfer its infectious disease research unit, which includes more than 100 employees to Evotec. Sanofi will pay Evotec an initial one-time cash upfront payment of EUR 60 m and provide further significant long-term funding to ensure support and progression of the portfolio. Sanofi will retain certain option rights on the development, manufacturing, and commercialisation of anti-infective products.
This transaction is expected to close in the first half of 2018, subject to finalisation of definitive agreements and completion of the appropriate social process.
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, email@example.com
08-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Manfred Eigen Campus / Essener Bogen 7|
|Phone:||+49 (0)40 560 81-0|
|Fax:||+49 (0)40 560 81-222|
|Listed:||Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of Announcement||DGAP News Service|